A number of other research analysts have also recently commented on MEDP. Zacks Investment Research raised shares of Medpace from a hold rating to a buy rating and set a $71.00 target price for the company in a report on Wednesday, July 10th. ValuEngine raised Medpace from a hold rating to a buy rating in a research note on Tuesday, July 2nd. SunTrust Banks upped their price objective on Medpace to $85.00 and gave the company a buy rating in a research note on Wednesday, July 31st. Credit Suisse Group upped their price objective on Medpace from $65.00 to $77.00 and gave the company an outperform rating in a research note on Tuesday, July 30th. Finally, TheStreet raised Medpace from a c rating to a b- rating in a research note on Thursday, June 6th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Medpace currently has a consensus rating of Buy and a consensus target price of $73.75.
MEDP stock opened at $75.54 on Friday. The company has a market capitalization of $2.75 billion, a PE ratio of 29.17, a P/E/G ratio of 2.10 and a beta of 1.57. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.66 and a quick ratio of 0.69. Medpace has a 12 month low of $45.88 and a 12 month high of $80.65. The business has a 50-day moving average of $65.10.
Several institutional investors have recently added to or reduced their stakes in the company. FTB Advisors Inc. increased its position in Medpace by 171.8% during the 2nd quarter. FTB Advisors Inc. now owns 579 shares of the company’s stock valued at $37,000 after purchasing an additional 366 shares during the period. Advisor Group Inc. increased its position in Medpace by 18.7% during the 2nd quarter. Advisor Group Inc. now owns 1,462 shares of the company’s stock valued at $95,000 after purchasing an additional 230 shares during the period. Marshall Wace LLP acquired a new stake in Medpace during the 1st quarter valued at approximately $99,000. LS Investment Advisors LLC increased its position in Medpace by 215.5% during the 1st quarter. LS Investment Advisors LLC now owns 2,745 shares of the company’s stock valued at $162,000 after purchasing an additional 1,875 shares during the period. Finally, South Dakota Investment Council acquired a new stake in Medpace during the 1st quarter valued at approximately $189,000. 77.39% of the stock is owned by institutional investors.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.